Table 2.
Identification of SIM2-derived HLA-A2.1-binding epitopes.
| Epitope | Sequence | SYFPEITHI score |
Binding (FI) |
|---|---|---|---|
| SIM2(25) | KLLPLPSAI | 25 | 3.22 |
| SIM2(84) | LLQTLDGFV | 23 | 1.88 |
| SIM2(87) | TLDGFVFVV | 27 | 5.43 |
| SIM2(167) | VLAKRNAGL | 26 | 0.82 |
| SIM2(174) | GLTCSGYKV | 23 | 1.1 |
| SIM2(199) | SLYDSCYQI | 23 | 4.39 |
| SIM2(205) | YQIVGLVAV | 23 | 3.82 |
| SIM2(237) | SLDLKLIFL | 27 | 1.7 |
| SIM2(241) | KLIFLDSRV | 23 | 2 |
| SIM2(244) | FLDSRVTEV | 27 | 4.75 |
| SIM2(339) | ELQLSLEQV | 21 | 1.28 |
| SIM2(430) | LLYTPSYSL | 27 | 2.61 |
| SIM2(527) | GSGLLVGKV | 18 | 0.82 |
| SIM2(530) | LLVGKVGGL | 30 | 0.97 |
| SIM2(558) | SRFGQTCPL | 17 | 0.88 |
| flu-M1 | GILGFVFTL | 30 | 3.17 |
| NEG | IAGNSAYEY | 9 | 1 |
Prediction algorithms were used to predict SIM2-derived, HLA-A2.1-binding epitopes. Also shown are peptides scores predicted by the algorithm SYFPEITHI. Binding of predicted peptides to HLA-A2.1 was assessed using the assembly assay on T2 cells in vitro. Out of the 15 peptides we tested, 9 showed binding ability, as compared to a non-binding peptide (NEG).